Resultado de búsqueda
The QuikChange II system is the second generation of Agilent’s QuikChange method. It provides improved fidelity over the original kit while maintaining greater than 80% mutation efficiency for single site mutagenesis. The kit includes PfuUltra High-Fidelity DNA Polymerase to minimize unwanted errors.
- QuikChange Primer Design
The QuikChange® Primer Design Program supports mutagenic...
- Nucleic Acid Calculators
www.chem.agilent.com
- Common Request Quote
Welcome, Guest. To request a quote, enter your information...
- QuikChange Primer Design
The QuikChange II site-directed mutagenesis method is performed using Pfu Ultra high-fidelity (HF) DNA polymerase for mutagenic primer-directed replication of both plasmid strands with the highest fidelity.
Agilent’s QuikChange Site-Directed Mutagenesis Kits speed up and simplify site-directed mutagenesis studies. Reduce unwanted errors and eliminate the need for sub-cloning into M13-based bacteriophage vectors and for ss-DNA rescue.
The QuickChange II 1-Day Site-Directed Mutagenesis Method: 1. Mutant strand synthesis. 2. Dpn I Digestion of parental DNA template. 3. Transformation of the resulting double-stranded nicked DNA molecules. After transformation, the XL10 Gold E. coli cell repairs nicks in the plasmid.
The QuikChange II One-Day Site-Directed Mutagenesis Method: 1. Mutant strand synthesis. 2. Dpn I Digestion of parental DNA template. 3. Transformation of the resulting annealed double-stranded nicked DNA molecules. After transformation, the XL-1 Blue E. coli cell repairs nicks in the plasmid.
QuikChange II-E Site-Directed Mutagenesis Kit . Instruction Manual. Catalog # 200555. Revision E1. For Research Use Only. Not for use in diagnostic procedures. 200555-12. LIMITED PRODUCT WARRANTY. This warranty limits our liability to replacement of this product.
The QuikChange site-directed mutagenesis method is performed using a proof-reading DNA polymerase cycler. The basic procedure utilizes a supercoiled double-stranded DNA (dsDNA) vector with an insert of interest and two synthetic oligonucleotide primers containing the desired mutation.
